SCHEMBL7513878

SCHEMBL7513878

CC(=O)Oc1c2c(c3ccccc3c1OC(C)=O)NC(=O)C2(C)C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 6/20 0.42
▸ HTT P42858 4/20 0.42
▸ MAPT P10636 4/20 0.42
▸ HSD17B10 Q99714 2/20 0.42
▸ TP53 P04637 1/20 0.42
▸ GAA P10253 1/20 0.42
▸ ABCB11 O95342 1/20 0.38
▸ POLB P06746 1/20 0.38
▸ TSHR P16473 1/20 0.38
▸ SLC22A6 Q4U2R8 1/20 0.37
▸ ALDH1A1 P00352 4/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ PDK2 Q15119 2/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.35
▸ GSK3B P49841 1/20 0.35
▸ ADK P55263 1/20 0.35
▸ NPC1 O15118 1/20 0.34
▸ RAB9A P51151 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24774791 0.79 KDM4E (0.44) KDM4EMAPTTP53POLBALDH1A1
SCHEMBL29922149 0.79 KDM4E (0.44) KDM4EMAPTTP53POLBALDH1A1
SCHEMBL11780453 0.74 KDM4E (0.61) KDM4EHTTMAPTHSD17B10TP53
SCHEMBL29368738 0.72 KDM4E (0.63) KDM4EHTTMAPTHSD17B10TP53
SCHEMBL6907648 0.72 KDM4E (0.63) KDM4EHTTMAPTHSD17B10TP53
SCHEMBL9643280 0.69 ABCB11 (0.64) KDM4EHTTMAPTHSD17B10TP53
SCHEMBL9642040 0.68 ABCB11 (0.62) KDM4EHTTMAPTHSD17B10TP53
SCHEMBL9713872 0.68 KDM4E (0.59) KDM4EHTTMAPTHSD17B10TP53
SCHEMBL13666895 0.67 KDM4E (0.62) KDM4EHTTMAPTHSD17B10TP53
SCHEMBL4236124 0.67 HTT (0.40) KDM4EHTTMAPTHSD17B10TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6498182-B2 BENZO(G)INDOLE -2,5(3H)-DIONE AND -2-ONE DERIVATIVE ANTIDIABETIC AGENTS BIOVITRUM AB (SE) 2002-12-24 — — US claimed
US-20020061921-A1 Novel compounds BIOVITRUM AB (SE) 2002-05-23 — — US claimed
WO-2002026707-A1 NOVEL COMPOUNDS BIOVITRUM AB (SE) 2002-04-04 — — WO claimed
US-6498182-B2 BENZO(G)INDOLE -2,5(3H)-DIONE AND -2-ONE DERIVATIVE ANTIDIABETIC AGENTS BIOVITRUM AB (SE) 2002-12-24 — — US disclosed
US-20020061921-A1 Novel compounds BIOVITRUM AB (SE) 2002-05-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020061921-A1 Novel compounds GPR119, IAPP, GLP1R KDM4E 3099/4885HTT 4679/4885MAPT 4596/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback